SGLT2 inhibitors benefit HF patients (HFrEF, HFmrEF, and HFpEF) most probably due to diuresis, improved cardiomyocyte metabolism, increased erythropoietin (EPO) release, and modifications in cardiac ion channels. This evidence concerns the gene SLC5A2 and hydrops fetalis.